Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tracon Pharma Says PD-L1 Passes Interim Safety Test in Sarcoma Trial

publication date: Oct 7, 2022

San Diego’s Tracon Pharma reported its PD-L1 candidate passed an interim test in a pivotal US-UK Phase II trial as a third-line therapy in soft tissue sarcomas. The Data Monitoring Committee recommended continuing the trial after a review of the 12-week safety data. In 2019, Tracon acquired US rights to develop envafolimab, an injected PD-L1 single-domain antibody, from Jiangsu Alphamab Oncology and 3D Medicines (Beijing). The trial is testing envafolimab in patients with undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS). In late 2021, Alphamab and 3D Medicines were approved to launch envafolimab in China. More details....

Stock Symbol: (NSDQ: TCOM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital